ArticleBMC neurology2026
Urinary proteomic profiling reveals diagnostic biomarkers and regulatory networks in myasthenia gravis.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated transcriptomic and proteomic analyses identify novel biomarkers of bladder outlet obstruction.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMyasthenia gravis (MG) is a chronic autoimmune neuromuscular junction disorder mediated by autoantibodies. Existing diagnostic methods mainly rely on serum antibody detection and electrophysiological testing, which are limited by invasiveness and suboptimal sensitivity and specificity. This study aimed to identify potential urinary biomarkers for noninvasive MG diagnosis using proteomics.
methodsData-independent acquisition (DIA) proteomic profiling was performed using a high-resolution Orbitrap Astral mass spectrometer on urine samples from 10 MG patients and 10 healthy controls. Differentially expressed proteins (DEPs) were identified and analyzed through Gene Ontology and KEGG pathway enrichment. LASSO regression and support vector machine models were applied to identify hub diagnostic proteins. The expression and diagnostic performance of the hub protein TPD52 were further validated in an independent cohort of 34 participants using ELISA.
resultsA total of 2,003 urinary proteins were identified between MG patients and healthy controls, among which 216 were significantly differentially expressed (|fold change| ≥ 1.2, p < 0.05). Enrichment analysis revealed that these DEPs were associated with neurodegenerative and neuroinflammatory diseases. Eight key proteins (TPD52, SORL1, PLAU, TSPAN3, CASP14, QPCT, CILP2, and CTHRC1) were identified by both LASSO and SVM algorithms, all exhibiting strong diagnostic performance (AUC > 0.76). In the independent validation cohort, the urinary expression of TPD52 was confirmed to be significantly elevated in MG patients, and ROC analysis yielded an AUC of 0.746, supporting its potential diagnostic value.
conclusionThis pilot urinary proteomic study provides preliminary evidence for urinary TPD52 as a potential noninvasive biomarker for MG and suggests its possible involvement in MG pathogenesis. These findings offer new insights into the molecular mechanisms of MG and lay a foundation for applying urinary proteomics in neuroimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.